Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules
Identifieur interne : 003572 ( Main/Exploration ); précédent : 003571; suivant : 003573Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules
Auteurs : Ryoko Sakai [Japon] ; Michi Tanaka [Japon] ; Toshihiro Nanki [Japon] ; Kaori Watanabe [Japon] ; Hayato Yamazaki [Japon] ; Ryuji Koike [Japon] ; Hayato Nagasawa [Japon] ; Koichi Amano [Japon] ; Kazuyoshi Saito [Japon] ; Yoshiya Tanaka [Japon] ; Satoshi Ito [Japon] ; Takayuki Sumida [Japon] ; Atsushi Ihata [Japon] ; Yoshiaki Ishigatsubo [Japon] ; Tatsuya Atsumi [Japon] ; Takao Koike [Japon] ; Atsuo Nakajima [Japon] ; Naoto Tamura [Japon] ; Takao Fujii [Japon] ; Hiroaki Dobashi [Japon] ; Shigeto Tohma [Japon] ; Takahiko Sugihara [Japon] ; Yukitaka Ueki [Japon] ; Akira Hashiramoto [Japon] ; Atsushi Kawakami [Japon] ; Noboru Hagino [Japon] ; Nobuyuki Miyasaka [Japon] ; Masayoshi Harigai [Japon]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2012-11.
Descripteurs français
- KwdFr :
- Abstention thérapeutique, Adulte d'âge moyen, Anticorps monoclonaux (effets indésirables), Anticorps monoclonaux humanisés (effets indésirables), Antirhumatismaux (effets indésirables), Enregistrements, Estimation de Kaplan-Meier, Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs), Facteurs de risque, Femelle, Humains, Immunoglobuline G (effets indésirables), Infliximab, Modèles de hasards proportionnels, Mâle, Polyarthrite rhumatoïde (traitement médicamenteux), Récepteurs aux facteurs de nécrose tumorale, Taux de survie, Étanercept, Études prospectives.
- MESH :
- antagonistes et inhibiteurs : Facteur de nécrose tumorale alpha.
- effets indésirables : Anticorps monoclonaux, Anticorps monoclonaux humanisés, Antirhumatismaux, Immunoglobuline G.
- traitement médicamenteux : Polyarthrite rhumatoïde.
- Pascal (Inist)
- MESH :
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Antibodies, Monoclonal (adverse effects), Antibodies, Monoclonal, Humanized (adverse effects), Antirheumatic Agents (adverse effects), Arthritis, Rheumatoid (drug therapy), Chronic, Etanercept, Female, Human, Humans, Immunoglobulin G (adverse effects), Infliximab, Kaplan-Meier Estimate, Male, Middle Aged, Proportional Hazards Models, Prospective Studies, Receptors, Tumor Necrosis Factor, Registries, Rheumatoid arthritis, Rheumatology, Risk Factors, Risk factor, Secondary effect, Survival Rate, Toxicity, Treatment, Tumor Necrosis Factor-alpha (antagonists & inhibitors), Withholding Treatment.
- MESH :
- chemical , adverse effects : Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Immunoglobulin G.
- chemical , antagonists & inhibitors : Tumor Necrosis Factor-alpha.
- drug therapy : Arthritis, Rheumatoid.
- Teeft :
- Abbott japan, Adverse events, Antirheumatic, Antirheumatic drugs, Arthritis, Arthritis patients, Arthritis rheum, Astellas pharma, Baseline, Biological agent, Biological agents, Biological dmard, Chugai, Clinical practice, Database, Dental sciences, Dental university, Dental university hospital, Discontinuation, Discontinuation rate, Disease activity, Disease activity score, Disease duration, Dmard, Drug discontinuation, Drug retention rates, Enrolment, Epidemiological, Epidemiological research, Epidemiological research table, Etanercept, Etanercept group, Female, Frequent reason, Good control, Graduate school, Higher percentages, Humans, Immunosuppressive drugs, Infliximab, Internal medicine, Kaplan-Meier Estimate, Male, Methotrexate, Middle Aged, Mitsubishi tanabe pharma, More dmard, Multivariate, Multivariate analysis, Nationwide danish danbio registry, Observation period, Pharma, Postmarketing surveillance, Proportional Hazards Models, Prospective Studies, Real database, Real study group, Receptors, Tumor Necrosis Factor, Registries, Remission, Retention rates, Rheum, Rheumatoid, Rheumatoid arthritis, Rheumatoid arthritis patients, Rheumatol, Rheumatology, Risk Factors, Risk factors, Site investigators, Successful discontinuation, Survival Rate, Tocilizumab, Tocilizumab group, Tocilizumab groups, Treatment discontinuation, Univariate analysis, Withholding Treatment.
Abstract
Objective To compare reasons for discontinuation and drug retention rates per reason among anticytokine therapies, infliximab, etanercept and tocilizumab, and the risk of discontinuation of biological agents due to adverse events (AE) in patients with rheumatoid arthritis (RA). Method This prospective cohort study included Japanese RA patients who started infliximab (n=412, 636.0 patient-years (PY)), etanercept (n=442, 765.3 PY), or tocilizumab (n=168, 206.5 PY) as the first biological therapy after their enrolment in the Registry of Japanese Rheumatoid Arthritis Patients for Long-term Safety (REAL) database. Drug retention rates were calculated using the Kaplan–Meier method. To compare risks of drug discontinuation due to AE for patients treated with these biological agents, the Cox proportional hazard model was applied. Results The authors found significant differences among the three therapeutic groups in demography, clinical status, comorbidities and usage of concomitant drugs. Development of AE was the most frequent reason for discontinuation of biological agents in the etanercept and tocilizumab groups, and the second most frequent reason in the infliximab group. Discontinuation due to good control was observed most frequently in the infliximab group. Compared with etanercept, the use of infliximab (HR 1.69; 95% CI 1.14 to 2.51) and tocilizumab (HR 1.98; 95% CI 1.04 to 3.76) was significantly associated with a higher risk of discontinuation of biological agents due to AE. Conclusions Reasons for discontinuation are significantly different among biological agents. The use of infliximab and tocilizumab was significantly associated with treatment discontinuation due to AE compared with etanercept.
Url:
DOI: 10.1136/annrheumdis-2011-200838
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000349
- to stream Istex, to step Curation: 000349
- to stream Istex, to step Checkpoint: 000E87
- to stream PubMed, to step Corpus: 001874
- to stream PubMed, to step Curation: 001874
- to stream PubMed, to step Checkpoint: 001781
- to stream Ncbi, to step Merge: 000577
- to stream Ncbi, to step Curation: 000577
- to stream Ncbi, to step Checkpoint: 000577
- to stream Main, to step Merge: 003598
- to stream PascalFrancis, to step Corpus: 000077
- to stream PascalFrancis, to step Curation: 000187
- to stream PascalFrancis, to step Checkpoint: 000110
- to stream Main, to step Merge: 003876
- to stream Main, to step Curation: 003572
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules</title><author><name sortKey="Sakai, Ryoko" sort="Sakai, Ryoko" uniqKey="Sakai R" first="Ryoko" last="Sakai">Ryoko Sakai</name></author><author><name sortKey="Tanaka, Michi" sort="Tanaka, Michi" uniqKey="Tanaka M" first="Michi" last="Tanaka">Michi Tanaka</name></author><author><name sortKey="Nanki, Toshihiro" sort="Nanki, Toshihiro" uniqKey="Nanki T" first="Toshihiro" last="Nanki">Toshihiro Nanki</name></author><author><name sortKey="Watanabe, Kaori" sort="Watanabe, Kaori" uniqKey="Watanabe K" first="Kaori" last="Watanabe">Kaori Watanabe</name></author><author><name sortKey="Yamazaki, Hayato" sort="Yamazaki, Hayato" uniqKey="Yamazaki H" first="Hayato" last="Yamazaki">Hayato Yamazaki</name></author><author><name sortKey="Koike, Ryuji" sort="Koike, Ryuji" uniqKey="Koike R" first="Ryuji" last="Koike">Ryuji Koike</name></author><author><name sortKey="Nagasawa, Hayato" sort="Nagasawa, Hayato" uniqKey="Nagasawa H" first="Hayato" last="Nagasawa">Hayato Nagasawa</name></author><author><name sortKey="Amano, Koichi" sort="Amano, Koichi" uniqKey="Amano K" first="Koichi" last="Amano">Koichi Amano</name></author><author><name sortKey="Saito, Kazuyoshi" sort="Saito, Kazuyoshi" uniqKey="Saito K" first="Kazuyoshi" last="Saito">Kazuyoshi Saito</name></author><author><name sortKey="Tanaka, Yoshiya" sort="Tanaka, Yoshiya" uniqKey="Tanaka Y" first="Yoshiya" last="Tanaka">Yoshiya Tanaka</name></author><author><name sortKey="Ito, Satoshi" sort="Ito, Satoshi" uniqKey="Ito S" first="Satoshi" last="Ito">Satoshi Ito</name></author><author><name sortKey="Sumida, Takayuki" sort="Sumida, Takayuki" uniqKey="Sumida T" first="Takayuki" last="Sumida">Takayuki Sumida</name></author><author><name sortKey="Ihata, Atsushi" sort="Ihata, Atsushi" uniqKey="Ihata A" first="Atsushi" last="Ihata">Atsushi Ihata</name></author><author><name sortKey="Ishigatsubo, Yoshiaki" sort="Ishigatsubo, Yoshiaki" uniqKey="Ishigatsubo Y" first="Yoshiaki" last="Ishigatsubo">Yoshiaki Ishigatsubo</name></author><author><name sortKey="Atsumi, Tatsuya" sort="Atsumi, Tatsuya" uniqKey="Atsumi T" first="Tatsuya" last="Atsumi">Tatsuya Atsumi</name></author><author><name sortKey="Koike, Takao" sort="Koike, Takao" uniqKey="Koike T" first="Takao" last="Koike">Takao Koike</name></author><author><name sortKey="Nakajima, Atsuo" sort="Nakajima, Atsuo" uniqKey="Nakajima A" first="Atsuo" last="Nakajima">Atsuo Nakajima</name></author><author><name sortKey="Tamura, Naoto" sort="Tamura, Naoto" uniqKey="Tamura N" first="Naoto" last="Tamura">Naoto Tamura</name></author><author><name sortKey="Fujii, Takao" sort="Fujii, Takao" uniqKey="Fujii T" first="Takao" last="Fujii">Takao Fujii</name></author><author><name sortKey="Dobashi, Hiroaki" sort="Dobashi, Hiroaki" uniqKey="Dobashi H" first="Hiroaki" last="Dobashi">Hiroaki Dobashi</name></author><author><name sortKey="Tohma, Shigeto" sort="Tohma, Shigeto" uniqKey="Tohma S" first="Shigeto" last="Tohma">Shigeto Tohma</name></author><author><name sortKey="Sugihara, Takahiko" sort="Sugihara, Takahiko" uniqKey="Sugihara T" first="Takahiko" last="Sugihara">Takahiko Sugihara</name></author><author><name sortKey="Ueki, Yukitaka" sort="Ueki, Yukitaka" uniqKey="Ueki Y" first="Yukitaka" last="Ueki">Yukitaka Ueki</name></author><author><name sortKey="Hashiramoto, Akira" sort="Hashiramoto, Akira" uniqKey="Hashiramoto A" first="Akira" last="Hashiramoto">Akira Hashiramoto</name></author><author><name sortKey="Kawakami, Atsushi" sort="Kawakami, Atsushi" uniqKey="Kawakami A" first="Atsushi" last="Kawakami">Atsushi Kawakami</name></author><author><name sortKey="Hagino, Noboru" sort="Hagino, Noboru" uniqKey="Hagino N" first="Noboru" last="Hagino">Noboru Hagino</name></author><author><name sortKey="Miyasaka, Nobuyuki" sort="Miyasaka, Nobuyuki" uniqKey="Miyasaka N" first="Nobuyuki" last="Miyasaka">Nobuyuki Miyasaka</name></author><author><name sortKey="Harigai, Masayoshi" sort="Harigai, Masayoshi" uniqKey="Harigai M" first="Masayoshi" last="Harigai">Masayoshi Harigai</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:069065E97351EE5FDB30D5D023588EC095B04CBC</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1136/annrheumdis-2011-200838</idno><idno type="url">https://api.istex.fr/ark:/67375/NVC-LSXF97TQ-0/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000349</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000349</idno><idno type="wicri:Area/Istex/Curation">000349</idno><idno type="wicri:Area/Istex/Checkpoint">000E87</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000E87</idno><idno type="wicri:doubleKey">0003-4967:2012:Sakai R:drug:retention:rates</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:22504558</idno><idno type="wicri:Area/PubMed/Corpus">001874</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001874</idno><idno type="wicri:Area/PubMed/Curation">001874</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001874</idno><idno type="wicri:Area/PubMed/Checkpoint">001781</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001781</idno><idno type="wicri:Area/Ncbi/Merge">000577</idno><idno type="wicri:Area/Ncbi/Curation">000577</idno><idno type="wicri:Area/Ncbi/Checkpoint">000577</idno><idno type="wicri:Area/Main/Merge">003598</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:12-0413249</idno><idno type="wicri:Area/PascalFrancis/Corpus">000077</idno><idno type="wicri:Area/PascalFrancis/Curation">000187</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000110</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000110</idno><idno type="wicri:doubleKey">0003-4967:2012:Sakai R:drug:retention:rates</idno><idno type="wicri:Area/Main/Merge">003876</idno><idno type="wicri:Area/Main/Curation">003572</idno><idno type="wicri:Area/Main/Exploration">003572</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules</title><author><name sortKey="Sakai, Ryoko" sort="Sakai, Ryoko" uniqKey="Sakai R" first="Ryoko" last="Sakai">Ryoko Sakai</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pharmacovigilance, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Tanaka, Michi" sort="Tanaka, Michi" uniqKey="Tanaka M" first="Michi" last="Tanaka">Michi Tanaka</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pharmacovigilance, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Nanki, Toshihiro" sort="Nanki, Toshihiro" uniqKey="Nanki T" first="Toshihiro" last="Nanki">Toshihiro Nanki</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pharmacovigilance, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Watanabe, Kaori" sort="Watanabe, Kaori" uniqKey="Watanabe K" first="Kaori" last="Watanabe">Kaori Watanabe</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pharmacovigilance, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Yamazaki, Hayato" sort="Yamazaki, Hayato" uniqKey="Yamazaki H" first="Hayato" last="Yamazaki">Hayato Yamazaki</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pharmacovigilance, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Koike, Ryuji" sort="Koike, Ryuji" uniqKey="Koike R" first="Ryuji" last="Koike">Ryuji Koike</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pharmacovigilance, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Clinical Research Center, Tokyo Medical and Dental University Hospital, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Nagasawa, Hayato" sort="Nagasawa, Hayato" uniqKey="Nagasawa H" first="Hayato" last="Nagasawa">Hayato Nagasawa</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Rheumatology/Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe</wicri:regionArea><wicri:noRegion>Kawagoe</wicri:noRegion></affiliation></author><author><name sortKey="Amano, Koichi" sort="Amano, Koichi" uniqKey="Amano K" first="Koichi" last="Amano">Koichi Amano</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Rheumatology/Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe</wicri:regionArea><wicri:noRegion>Kawagoe</wicri:noRegion></affiliation></author><author><name sortKey="Saito, Kazuyoshi" sort="Saito, Kazuyoshi" uniqKey="Saito K" first="Kazuyoshi" last="Saito">Kazuyoshi Saito</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu</wicri:regionArea><wicri:noRegion>Kitakyushu</wicri:noRegion></affiliation></author><author><name sortKey="Tanaka, Yoshiya" sort="Tanaka, Yoshiya" uniqKey="Tanaka Y" first="Yoshiya" last="Tanaka">Yoshiya Tanaka</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu</wicri:regionArea><wicri:noRegion>Kitakyushu</wicri:noRegion></affiliation></author><author><name sortKey="Ito, Satoshi" sort="Ito, Satoshi" uniqKey="Ito S" first="Satoshi" last="Ito">Satoshi Ito</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Clinical Immunology, Doctoral Program in Clinical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba</wicri:regionArea><wicri:noRegion>Tsukuba</wicri:noRegion></affiliation></author><author><name sortKey="Sumida, Takayuki" sort="Sumida, Takayuki" uniqKey="Sumida T" first="Takayuki" last="Sumida">Takayuki Sumida</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Division of Clinical Immunology, Doctoral Program in Clinical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba</wicri:regionArea><wicri:noRegion>Tsukuba</wicri:noRegion></affiliation></author><author><name sortKey="Ihata, Atsushi" sort="Ihata, Atsushi" uniqKey="Ihata A" first="Atsushi" last="Ihata">Atsushi Ihata</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama</wicri:regionArea><wicri:noRegion>Yokohama</wicri:noRegion></affiliation></author><author><name sortKey="Ishigatsubo, Yoshiaki" sort="Ishigatsubo, Yoshiaki" uniqKey="Ishigatsubo Y" first="Yoshiaki" last="Ishigatsubo">Yoshiaki Ishigatsubo</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama</wicri:regionArea><wicri:noRegion>Yokohama</wicri:noRegion></affiliation></author><author><name sortKey="Atsumi, Tatsuya" sort="Atsumi, Tatsuya" uniqKey="Atsumi T" first="Tatsuya" last="Atsumi">Tatsuya Atsumi</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Internal Medicine II, Hokkaido University, Graduate School of Medicine, Sapporo</wicri:regionArea><wicri:noRegion>Sapporo</wicri:noRegion></affiliation></author><author><name sortKey="Koike, Takao" sort="Koike, Takao" uniqKey="Koike T" first="Takao" last="Koike">Takao Koike</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Internal Medicine II, Hokkaido University, Graduate School of Medicine, Sapporo</wicri:regionArea><wicri:noRegion>Sapporo</wicri:noRegion></affiliation></author><author><name sortKey="Nakajima, Atsuo" sort="Nakajima, Atsuo" uniqKey="Nakajima A" first="Atsuo" last="Nakajima">Atsuo Nakajima</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Rheumatology, Tokyo Metropolitan Police Hospital, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Tamura, Naoto" sort="Tamura, Naoto" uniqKey="Tamura N" first="Naoto" last="Tamura">Naoto Tamura</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Fujii, Takao" sort="Fujii, Takao" uniqKey="Fujii T" first="Takao" last="Fujii">Takao Fujii</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto</wicri:regionArea><orgName type="university">Université de Kyoto</orgName><placeName><settlement type="city">Kyoto</settlement><region type="prefecture">Région du Kansai</region></placeName></affiliation></author><author><name sortKey="Dobashi, Hiroaki" sort="Dobashi, Hiroaki" uniqKey="Dobashi H" first="Hiroaki" last="Dobashi">Hiroaki Dobashi</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Internal Medicine, Division of Endocrinology and Metabolism, Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa</wicri:regionArea><wicri:noRegion>Kagawa</wicri:noRegion></affiliation></author><author><name sortKey="Tohma, Shigeto" sort="Tohma, Shigeto" uniqKey="Tohma S" first="Shigeto" last="Tohma">Shigeto Tohma</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Sagamihara</wicri:regionArea><wicri:noRegion>Sagamihara</wicri:noRegion></affiliation></author><author><name sortKey="Sugihara, Takahiko" sort="Sugihara, Takahiko" uniqKey="Sugihara T" first="Takahiko" last="Sugihara">Takahiko Sugihara</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Tokyo Metropolitan Geriatric Hospital, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Ueki, Yukitaka" sort="Ueki, Yukitaka" uniqKey="Ueki Y" first="Yukitaka" last="Ueki">Yukitaka Ueki</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Nagasaki</wicri:regionArea><wicri:noRegion>Nagasaki</wicri:noRegion></affiliation></author><author><name sortKey="Hashiramoto, Akira" sort="Hashiramoto, Akira" uniqKey="Hashiramoto A" first="Akira" last="Hashiramoto">Akira Hashiramoto</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Rheumatology, Kobe University Graduate School of Medicine, Kobe</wicri:regionArea><wicri:noRegion>Kobe</wicri:noRegion></affiliation></author><author><name sortKey="Kawakami, Atsushi" sort="Kawakami, Atsushi" uniqKey="Kawakami A" first="Atsushi" last="Kawakami">Atsushi Kawakami</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki</wicri:regionArea><wicri:noRegion>Nagasaki</wicri:noRegion></affiliation></author><author><name sortKey="Hagino, Noboru" sort="Hagino, Noboru" uniqKey="Hagino N" first="Noboru" last="Hagino">Noboru Hagino</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Allergy and Rheumatology, The University of Tokyo, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName><orgName type="university">Université de Tokyo</orgName></affiliation></author><author><name sortKey="Miyasaka, Nobuyuki" sort="Miyasaka, Nobuyuki" uniqKey="Miyasaka N" first="Nobuyuki" last="Miyasaka">Nobuyuki Miyasaka</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Global Center of Excellence (GCOE) Program; International Research Center for Molecular Science in Tooth and Bone Diseases, Tokyo Medical and Dental University, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Harigai, Masayoshi" sort="Harigai, Masayoshi" uniqKey="Harigai M" first="Masayoshi" last="Harigai">Masayoshi Harigai</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pharmacovigilance, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Medicine and Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Clinical Research Center, Tokyo Medical and Dental University Hospital, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2012-11">2012-11</date><biblScope unit="volume">71</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1820">1820</biblScope></imprint><idno type="ISSN">0003-4967</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0003-4967</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal (adverse effects)</term><term>Antibodies, Monoclonal, Humanized (adverse effects)</term><term>Antirheumatic Agents (adverse effects)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Chronic</term><term>Etanercept</term><term>Female</term><term>Human</term><term>Humans</term><term>Immunoglobulin G (adverse effects)</term><term>Infliximab</term><term>Kaplan-Meier Estimate</term><term>Male</term><term>Middle Aged</term><term>Proportional Hazards Models</term><term>Prospective Studies</term><term>Receptors, Tumor Necrosis Factor</term><term>Registries</term><term>Rheumatoid arthritis</term><term>Rheumatology</term><term>Risk Factors</term><term>Risk factor</term><term>Secondary effect</term><term>Survival Rate</term><term>Toxicity</term><term>Treatment</term><term>Tumor Necrosis Factor-alpha (antagonists & inhibitors)</term><term>Withholding Treatment</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Abstention thérapeutique</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux (effets indésirables)</term><term>Anticorps monoclonaux humanisés (effets indésirables)</term><term>Antirhumatismaux (effets indésirables)</term><term>Enregistrements</term><term>Estimation de Kaplan-Meier</term><term>Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs)</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Immunoglobuline G (effets indésirables)</term><term>Infliximab</term><term>Modèles de hasards proportionnels</term><term>Mâle</term><term>Polyarthrite rhumatoïde (traitement médicamenteux)</term><term>Récepteurs aux facteurs de nécrose tumorale</term><term>Taux de survie</term><term>Étanercept</term><term>Études prospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term><term>Immunoglobulin G</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de nécrose tumorale alpha</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term><term>Immunoglobuline G</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Chronique</term><term>Effet secondaire</term><term>Facteur risque</term><term>Homme</term><term>Polyarthrite rhumatoïde</term><term>Rhumatologie</term><term>Toxicité</term><term>Traitement</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Abbott japan</term><term>Adverse events</term><term>Antirheumatic</term><term>Antirheumatic drugs</term><term>Arthritis</term><term>Arthritis patients</term><term>Arthritis rheum</term><term>Astellas pharma</term><term>Baseline</term><term>Biological agent</term><term>Biological agents</term><term>Biological dmard</term><term>Chugai</term><term>Clinical practice</term><term>Database</term><term>Dental sciences</term><term>Dental university</term><term>Dental university hospital</term><term>Discontinuation</term><term>Discontinuation rate</term><term>Disease activity</term><term>Disease activity score</term><term>Disease duration</term><term>Dmard</term><term>Drug discontinuation</term><term>Drug retention rates</term><term>Enrolment</term><term>Epidemiological</term><term>Epidemiological research</term><term>Epidemiological research table</term><term>Etanercept</term><term>Etanercept group</term><term>Female</term><term>Frequent reason</term><term>Good control</term><term>Graduate school</term><term>Higher percentages</term><term>Humans</term><term>Immunosuppressive drugs</term><term>Infliximab</term><term>Internal medicine</term><term>Kaplan-Meier Estimate</term><term>Male</term><term>Methotrexate</term><term>Middle Aged</term><term>Mitsubishi tanabe pharma</term><term>More dmard</term><term>Multivariate</term><term>Multivariate analysis</term><term>Nationwide danish danbio registry</term><term>Observation period</term><term>Pharma</term><term>Postmarketing surveillance</term><term>Proportional Hazards Models</term><term>Prospective Studies</term><term>Real database</term><term>Real study group</term><term>Receptors, Tumor Necrosis Factor</term><term>Registries</term><term>Remission</term><term>Retention rates</term><term>Rheum</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatoid arthritis patients</term><term>Rheumatol</term><term>Rheumatology</term><term>Risk Factors</term><term>Risk factors</term><term>Site investigators</term><term>Successful discontinuation</term><term>Survival Rate</term><term>Tocilizumab</term><term>Tocilizumab group</term><term>Tocilizumab groups</term><term>Treatment discontinuation</term><term>Univariate analysis</term><term>Withholding Treatment</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Abstention thérapeutique</term><term>Adulte d'âge moyen</term><term>Enregistrements</term><term>Estimation de Kaplan-Meier</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Infliximab</term><term>Modèles de hasards proportionnels</term><term>Mâle</term><term>Récepteurs aux facteurs de nécrose tumorale</term><term>Taux de survie</term><term>Étanercept</term><term>Études prospectives</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Objective To compare reasons for discontinuation and drug retention rates per reason among anticytokine therapies, infliximab, etanercept and tocilizumab, and the risk of discontinuation of biological agents due to adverse events (AE) in patients with rheumatoid arthritis (RA). Method This prospective cohort study included Japanese RA patients who started infliximab (n=412, 636.0 patient-years (PY)), etanercept (n=442, 765.3 PY), or tocilizumab (n=168, 206.5 PY) as the first biological therapy after their enrolment in the Registry of Japanese Rheumatoid Arthritis Patients for Long-term Safety (REAL) database. Drug retention rates were calculated using the Kaplan–Meier method. To compare risks of drug discontinuation due to AE for patients treated with these biological agents, the Cox proportional hazard model was applied. Results The authors found significant differences among the three therapeutic groups in demography, clinical status, comorbidities and usage of concomitant drugs. Development of AE was the most frequent reason for discontinuation of biological agents in the etanercept and tocilizumab groups, and the second most frequent reason in the infliximab group. Discontinuation due to good control was observed most frequently in the infliximab group. Compared with etanercept, the use of infliximab (HR 1.69; 95% CI 1.14 to 2.51) and tocilizumab (HR 1.98; 95% CI 1.04 to 3.76) was significantly associated with a higher risk of discontinuation of biological agents due to AE. Conclusions Reasons for discontinuation are significantly different among biological agents. The use of infliximab and tocilizumab was significantly associated with treatment discontinuation due to AE compared with etanercept.</div></front></TEI><affiliations><list><country><li>Japon</li></country><region><li>Région de Kantō</li><li>Région du Kansai</li></region><settlement><li>Kyoto</li><li>Tokyo</li></settlement><orgName><li>Université de Kyoto</li><li>Université de Tokyo</li></orgName></list><tree><country name="Japon"><region name="Région de Kantō"><name sortKey="Sakai, Ryoko" sort="Sakai, Ryoko" uniqKey="Sakai R" first="Ryoko" last="Sakai">Ryoko Sakai</name></region><name sortKey="Amano, Koichi" sort="Amano, Koichi" uniqKey="Amano K" first="Koichi" last="Amano">Koichi Amano</name><name sortKey="Atsumi, Tatsuya" sort="Atsumi, Tatsuya" uniqKey="Atsumi T" first="Tatsuya" last="Atsumi">Tatsuya Atsumi</name><name sortKey="Dobashi, Hiroaki" sort="Dobashi, Hiroaki" uniqKey="Dobashi H" first="Hiroaki" last="Dobashi">Hiroaki Dobashi</name><name sortKey="Fujii, Takao" sort="Fujii, Takao" uniqKey="Fujii T" first="Takao" last="Fujii">Takao Fujii</name><name sortKey="Hagino, Noboru" sort="Hagino, Noboru" uniqKey="Hagino N" first="Noboru" last="Hagino">Noboru Hagino</name><name sortKey="Harigai, Masayoshi" sort="Harigai, Masayoshi" uniqKey="Harigai M" first="Masayoshi" last="Harigai">Masayoshi Harigai</name><name sortKey="Harigai, Masayoshi" sort="Harigai, Masayoshi" uniqKey="Harigai M" first="Masayoshi" last="Harigai">Masayoshi Harigai</name><name sortKey="Harigai, Masayoshi" sort="Harigai, Masayoshi" uniqKey="Harigai M" first="Masayoshi" last="Harigai">Masayoshi Harigai</name><name sortKey="Hashiramoto, Akira" sort="Hashiramoto, Akira" uniqKey="Hashiramoto A" first="Akira" last="Hashiramoto">Akira Hashiramoto</name><name sortKey="Ihata, Atsushi" sort="Ihata, Atsushi" uniqKey="Ihata A" first="Atsushi" last="Ihata">Atsushi Ihata</name><name sortKey="Ishigatsubo, Yoshiaki" sort="Ishigatsubo, Yoshiaki" uniqKey="Ishigatsubo Y" first="Yoshiaki" last="Ishigatsubo">Yoshiaki Ishigatsubo</name><name sortKey="Ito, Satoshi" sort="Ito, Satoshi" uniqKey="Ito S" first="Satoshi" last="Ito">Satoshi Ito</name><name sortKey="Kawakami, Atsushi" sort="Kawakami, Atsushi" uniqKey="Kawakami A" first="Atsushi" last="Kawakami">Atsushi Kawakami</name><name sortKey="Koike, Ryuji" sort="Koike, Ryuji" uniqKey="Koike R" first="Ryuji" last="Koike">Ryuji Koike</name><name sortKey="Koike, Ryuji" sort="Koike, Ryuji" uniqKey="Koike R" first="Ryuji" last="Koike">Ryuji Koike</name><name sortKey="Koike, Ryuji" sort="Koike, Ryuji" uniqKey="Koike R" first="Ryuji" last="Koike">Ryuji Koike</name><name sortKey="Koike, Takao" sort="Koike, Takao" uniqKey="Koike T" first="Takao" last="Koike">Takao Koike</name><name sortKey="Miyasaka, Nobuyuki" sort="Miyasaka, Nobuyuki" uniqKey="Miyasaka N" first="Nobuyuki" last="Miyasaka">Nobuyuki Miyasaka</name><name sortKey="Miyasaka, Nobuyuki" sort="Miyasaka, Nobuyuki" uniqKey="Miyasaka N" first="Nobuyuki" last="Miyasaka">Nobuyuki Miyasaka</name><name sortKey="Nagasawa, Hayato" sort="Nagasawa, Hayato" uniqKey="Nagasawa H" first="Hayato" last="Nagasawa">Hayato Nagasawa</name><name sortKey="Nakajima, Atsuo" sort="Nakajima, Atsuo" uniqKey="Nakajima A" first="Atsuo" last="Nakajima">Atsuo Nakajima</name><name sortKey="Nanki, Toshihiro" sort="Nanki, Toshihiro" uniqKey="Nanki T" first="Toshihiro" last="Nanki">Toshihiro Nanki</name><name sortKey="Nanki, Toshihiro" sort="Nanki, Toshihiro" uniqKey="Nanki T" first="Toshihiro" last="Nanki">Toshihiro Nanki</name><name sortKey="Saito, Kazuyoshi" sort="Saito, Kazuyoshi" uniqKey="Saito K" first="Kazuyoshi" last="Saito">Kazuyoshi Saito</name><name sortKey="Sakai, Ryoko" sort="Sakai, Ryoko" uniqKey="Sakai R" first="Ryoko" last="Sakai">Ryoko Sakai</name><name sortKey="Sugihara, Takahiko" sort="Sugihara, Takahiko" uniqKey="Sugihara T" first="Takahiko" last="Sugihara">Takahiko Sugihara</name><name sortKey="Sumida, Takayuki" sort="Sumida, Takayuki" uniqKey="Sumida T" first="Takayuki" last="Sumida">Takayuki Sumida</name><name sortKey="Tamura, Naoto" sort="Tamura, Naoto" uniqKey="Tamura N" first="Naoto" last="Tamura">Naoto Tamura</name><name sortKey="Tanaka, Michi" sort="Tanaka, Michi" uniqKey="Tanaka M" first="Michi" last="Tanaka">Michi Tanaka</name><name sortKey="Tanaka, Michi" sort="Tanaka, Michi" uniqKey="Tanaka M" first="Michi" last="Tanaka">Michi Tanaka</name><name sortKey="Tanaka, Yoshiya" sort="Tanaka, Yoshiya" uniqKey="Tanaka Y" first="Yoshiya" last="Tanaka">Yoshiya Tanaka</name><name sortKey="Tohma, Shigeto" sort="Tohma, Shigeto" uniqKey="Tohma S" first="Shigeto" last="Tohma">Shigeto Tohma</name><name sortKey="Ueki, Yukitaka" sort="Ueki, Yukitaka" uniqKey="Ueki Y" first="Yukitaka" last="Ueki">Yukitaka Ueki</name><name sortKey="Watanabe, Kaori" sort="Watanabe, Kaori" uniqKey="Watanabe K" first="Kaori" last="Watanabe">Kaori Watanabe</name><name sortKey="Watanabe, Kaori" sort="Watanabe, Kaori" uniqKey="Watanabe K" first="Kaori" last="Watanabe">Kaori Watanabe</name><name sortKey="Yamazaki, Hayato" sort="Yamazaki, Hayato" uniqKey="Yamazaki H" first="Hayato" last="Yamazaki">Hayato Yamazaki</name><name sortKey="Yamazaki, Hayato" sort="Yamazaki, Hayato" uniqKey="Yamazaki H" first="Hayato" last="Yamazaki">Hayato Yamazaki</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003572 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003572 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:069065E97351EE5FDB30D5D023588EC095B04CBC
|texte= Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules
}}
| This area was generated with Dilib version V0.6.34. |  |